TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preparation (claimed): Producing a cellulase variant comprises culturing the host cell in a culture medium, under suitable conditions to produce the cellulase variant. Preferred Variant: The variant comprises a further substitution at one or more further positions selected from: (a)a first group consisting of 63, 77, 129, 146, 147, 151, 153, 157, 161, 189, 194, 197, 203, 204, 208, 211, 237, 239, 244, 247, 254, 277, 281, 285, 288, 289, 294, 327, 339, 344, 356, 378, 382 and 405; or (b) a second group consisting of 94, 98, 107, 120, 134, 144, 154, 178, 179, 206, 210, 214, 231, 232, 266, 272, 275, 291, 312, 316, 323, 343, 360, 380, 381, 386, 399, 410, 413, 416, 426, and 429, where the further positions are numbered by correspondence with the amino acid sequence of the reference CBH2 set forth as SEQ ID NO. 3. The variant is a mature form having cellulase activity and comprising a substitution at one or more positions selected from the group consisting of: 63, 77, 129, 146, 147, 151, 153, 157, 161, 189, 194, 197, 203, 204, 208, 211, 237, 239, 244, 247, 254, 277, 281, 285, 288, 289, 294, 327, 339, 344, 356, 378, 382 and 405, where the positions are numbered by correspondence with the amino acid sequence of a reference CBH2 set forth as SEQ ID NO. 3, and where when the cellulase variant consists of a single substitution, the single substitution is not a KIE, RIQ, NID, QIE, DIN or EIQ substitution. The variant comprises a further substitution at one or more further positions selected from: (a) a first group consisting of 5, 18, 19, 28, 30, 32, 35, 38, 79, 80, 89, 100, 102, 103, 104, 105, 111, 117, 119, 121, 125, 126, 133, 137, 138, 139, 140, 141, 143, 150, 158, 162, 177, 180, 181, 182, 185, 186, 188, 190, 191, 192, 193, 196, 201, 207, 225, 226, 228, 229, 230, 233, 234, 236, 240, 243, 245, 251, 252, 258, 267, 268, 274, 292, 293, 303, 304, 306, 307, 313, 319, 322, 328, 331, 338, 340, 346, 361, 362, 363, 364, 365, 371, 384, 394, 396, 400, 406, 407, 414, 417, 422, 427, 431, 433, 436, 440, 441, 443, 444, 445 and 447; or (b) a second group consisting of 94, 98, 107, 120, 134, 144, 154, 178, 179, 206, 210, 214, 231, 232, 266, 272, 275, 291, 312, 316, 323, 343, 360, 380, 381, 386, 399, 410, 413, 416, 426, and 429, where the further positions are numbered by correspondence with the amino acid sequence of the reference CBH2 set forth as SEQ ID NO. 3. The variant is a mature form having cellulase activity and comprising a substitution at one or more positions selected from: 94, 98, 107, 120, 134, 144, 154, 178, 179, 206, 210, 214, 231, 232, 266, 272, 275, 291, 312, 316, 323, 343, 360, 380, 381, 386, 399, 410, 413, 416, 426, and 429, where the positions are numbered by correspondence with the amino acid sequence of a reference CBH2 set forth as SEQ ID NO. 3, and where when the cellulase variant consists of a single substitution, the single substitution is not one of the group consisting of V94E, P98L, E1O7Q, M12OL, M134G, M134L, M134V, L144G, L144R, L1445, T154A, A178V, L179C, V206L, 5210L, 5210R, T214M, T214Y, G231P, G2311, G231A, G231N, G2315, G231T, T232V, H2665, H266A, W272A, W272D, W272Y, N275L, 5316P, V323L, V323N, V323Y, G360R, 5380T, A381T, E399N, E399D, R413Y, R413P, and A416G. The variant comprises a further substitution at one or more further positions selected from: (a) a first group consisting of 5, 18, 19, 28, 30, 32, 35, 38, 79, 80, 89, 100, 102, 103, 104, 105, 111, 117, 119, 121, 125, 126, 133, 137, 138, 139, 140, 141, 143, 150, 158, 162, 177, 180, 181, 182, 185, 186, 188, 190, 191, 192, 193, 196, 201, 207, 225, 226, 228, 229, 230, 233, 234, 236, 240, 243, 245, 251, 252, 258, 267, 268, 274, 292, 293, 303, 304, 306, 307, 313, 319, 322, 328, 331, 338, 340, 346, 361, 362, 363, 364, 365, 371, 384, 394, 396, 400, 406, 407, 414, 417, 422, 427, 431, 433, 436, 440, 441, 443, 444, 445 and 447; or (b) a second group consisting of 63,77, 129, 146, 147, 151, 153, 157, 161, 189, 194, 197, 203, 204, 208, 211, 237, 239, 244, 247, 254, 277, 281, 285, 288, 289, 294, 327, 339, 344, 356, 378, 382 and 405, where the further positions are numbered by correspondence with the amino acid sequence of the reference CBH2 set forth as SEQ ID NO. 3. The substitution at one or more positions is selected from 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 and 25 positions. The variant is a mature form having cellulase activity and comprising a substitution at from one to six positions selected from 111, 144, 154, 162, 410 and 413, where the cellulase variant comprises: leucine or serine at position 111; leucine, glutamine or tryptophan at position 144; threonine, cysteine or valine at position 154; tyrosine or asparagine at position 162; arginine or serine at position 410; and serine, tryptophan or tyrosine at position 413; where the positions are numbered by correspondence with the amino acid sequence of the reference CBH2 set forth as SEQ ID NO. 3, and where when the cellulase variant consists of a single substitution, the single substitution is not a 5413Y substitution. The variant is a mature form having cellulase activity and comprising a substitution at from one to six positions selected from the group consisting of 98, 194, 313, 316, 384 and 443, where the cellulase variant comprises: proline or leucine at position 98; lysine, cysteine or glutamic acid at position 194; serine or threonine at position 313; serine or proline at position 316; glycine, cysteine or glutamine at position 384; and asparagine or isoleucine at position 443; where the positions are numbered by correspondence with the amino acid sequence of the reference CBH2 set forth as SEQ ID NO. 3, and where when the cellulase variant consists of a single substitution, the single substitution is not one of the group selected from a P98L substitution, a K194E substitution, and a S316P substitution. The variant is a mature form having cellulase activity and comprising a substitution at from one to six positions selected from 153, 161, 203, 233, 422 and 444, where the cellulase variant comprises: arginine or glutamine at position 153; asparagine, alanine or tryptophan at position 161; arginine or histidine at position 203; proline or aspartic acid at position 233; glutamine or valine at position 422; and proline or glutamine at position 443; where the positions are numbered by correspondence with the amino acid sequence of the reference CBH2 set forth as SEQ ID NO. 3, and where when the cellulase variant consists of a single substitution, the single substitution is not a R153Q substitution. The variant is a mature form having cellulase activity and comprising a substitution at from one to seven positions selected from the group consisting of 98, 111, 144, 313, 316, 413 and 422, where the cellulase variant comprises: proline or leucine at position 98; leucine or serine at position 111; leucine or tryptophan at position 144; serine or threonine at position 313; serine or proline at position 316; serine or tryptophan at position 413; and glutamine or valine at position 422; where the positions are numbered by correspondence with the amino acid sequence of the reference CBH2 set forth as SEQ ID NO. 3, and where when the cellulase variant consists of a single substitution, the single substitution is not one of the group selected from a P98L substitution, and a 5316P substitution. It also comprises a glutamine at position 98, and a substitution selected from a T138C, a 5316P, a 5343Q, a Q3621, a 5386C, a C4005 and a 5406P, where the positions are numbered by correspondence with the amino acid sequence of the reference CBH2 set forth as SEQ ID NO. 3. It also comprise a cysteine at position 138, and a substitution selected from a 5316P, a 5343Q, a Q3621, a 5386C, a C4005 and a S406P, where the positions are numbered by correspondence with the amino acid sequence of the reference CBH2 set forth as SEQ ID NO. 3. It also comprises a proline at position 316, and a substitution selected from a 5343Q, a Q3621, a 5386C, a C4005 and a 5406P, where the positions are numbered by correspondence with the amino acid sequence of the reference CBH2 set forth as SEQ ID NO. 3. It also comprises a glutamine at position 343, and a substitution selected from a Q3621, a 5386C, a C4005 and a 5406P, where the positions are numbered by correspondence with the amino acid sequence of the reference CBH2 set forth as SEQ ID NO. 3. It also comprises an isoleucine at position 362, and a substitution selected from a 5386C, a C4005 and a 5406P, where the positions are numbered by correspondence with the amino acid sequence of the reference CBH2 set forth as SEQ ID NO. 3. It also comprises a cysteine at position 386, and a substitution selected from a C4005 and a 5406P, where the positions are numbered by correspondence with the amino acid sequence of the reference CBH2 set forth as SEQ ID NO. 3. It comprises a serine at position 400 and a proline at position 406. The variant is a mature form having cellulase activity and comprising a substitution at from one to seven positions selected from the group consisting of 98, 111, 182, 291, 316, 362 and 400, where the cellulase variant comprises: proline, leucine or glutamine at position 98; leucine or serine at position 111; aspargine or tryptophan at position 182; serine or a glutamic acid at position 291; serine or proline at position 316; glutamine, isoleucine or leucine at position 362; and cysteine or serine at position 400; where the positions are numbered by correspondence with the amino acid sequence of the reference CBH2 set forth as SEQ ID NO. 3, and where when the cellulase variant consists of a single substitution, the single substitution is not one of the group selected from a P98L substitution, and a S316P substitution. The variant further comprises a L439P substitution or a T74S substitution. The variant is derived from a parent cellulase selected from Hypocrea jecorina CBH2, Hypocrea koningii CBH2, Hunzicola insolens CBH2, Acrenioniuni cellulolyticus CBH2, Agaricus bisporus CBH2, Fusarium osysporuni EG, Phanerochaete chrysosporium CBH2, Talaronzyces enzersonii CBH2, Thermobifida fusca 6B/E3 CBH2, Thermobifida fusca 6A/E2 EG, and Cellulomonas finzi CenA EG. The variant is derived from a parent cellulase whose amino acid sequence is at least 75% 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a member of the group consisting of SEQ ID NO. 3-13. The variant is isolated. Preferred Composition: The composition is enriched in the cellulase variant. It further comprises at least one additional enzyme selected from a subtilisin, a neutral metalloprotease, a lipase, a cutinase, an amylase, a carbohydrase, a pectinase, a mannanase, an arabinase, a galactanase, a xylanase, an oxidase, and a peroxidase. EXAMPLE - No suitable example given.